- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00671996
Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C (MANFOL)
A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mangafodipir, manganese (Mn) dipyridoxyl diphosphate, is a catalytic antioxidant and iron chelator recently (2006) suggested for cancer treatment in an Editorial in Journal of the National Cancer Institute. Preclinical research has shown that mangafodipir protects normal tissues without loss of anti-tumour activity during chemotherapy. Other advantages are that mangafodipir is already approved for use in patients as a contrast agent for magnetic resonance imaging (MRI) of liver, and that the experience for more than a decade reveals high safety with mainly minor and tolerable side-effects.
The present study will include 14 patients who will be followed throughout 3 treatment cycles. Each cycle will be preceded by infusion of mangafodipir or placebo in two groups, each consisting of 7 patients. The primary endpoints will be the most frequent manifestation of FOLFOX6, namely neutropenia and neurosensory toxicity. The secondary endpoints will be the frequency and severity of other FOLFOX6-related adverse events and quality of life.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Jönköping, Sweden, SE-551 85
- Onkologkliniken, Länssjukhuset Ryhov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven colon cancer stage Dukes' C.
- Patient over 18 years.
- WHO performance status <1.
- Adequate haematological function (Hb ≥ 100 g/L, ANC ≥ 2.0 x 109/L, platelets ≥ 150 x 109/L)
- Adequate renal and hepatic functions: serum creatinine and total bilirubin ≤ 1.25 times upper normal limits (ASAT and ALAT ≤ 3 times upper normal limits)
- Clinical evaluation, haematology and biochemistry performed within 1 week prior to the start of chemotherapy
- Use of adequate contraception (males with reproductive potential)
- Written informed consent given
Exclusion Criteria:
- Other tumour types than colon adenocarcinomas
- Current severe neutropenia, leucopenia or thrombocytopenia
- Severely reduced liver or renal function
- Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or ulcerative colitis
- Current chronic diarrhoea
- Contraindication for corticosteroid administration
- History of prior serious allergic or pseudo-allergic reaction
- Any other serious illness or medical condition
- Symptomatic peripheral neuropathy ≥ grade 2
- Received mangafodipir ≤ 5 weeks before planned start of chemotherapy
- Received any of the FOLFOX drugs ≤ 5 weeks before planned start of chemotherapy
- Any plans of administered other anti-cancer therapy (including radiotherapy) concurrent with this study
- Fertile females
- Males with reproductive potential not implementing adequate contraception measures
- Phaeochromocytoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: B
|
Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
|
Active Comparator: A
Mangafodipir treatment
|
Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neutropenia
Time Frame: Before and after completion of one, two and/or three FOLFOX6-cycles
|
Before and after completion of one, two and/or three FOLFOX6-cycles
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of Life
Time Frame: Before and after completion of one, two and/or three FOLFOX6-cycles
|
Before and after completion of one, two and/or three FOLFOX6-cycles
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ursula Falkmer, MD, PhD, Lanssjukhuset Ryhov
Publications and helpful links
General Publications
- Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, Batteux F. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006 Feb 15;98(4):236-44. doi: 10.1093/jnci/djj049.
- Asplund A, Grant D, Karlsson JO. Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries. J Pharmacol Exp Ther. 1994 Nov;271(2):609-14.
- Brurok H, Ardenkjaer-Larsen JH, Hansson G, Skarra S, Berg K, Karlsson JO, Laursen I, Jynge P. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties? Biochem Biophys Res Commun. 1999 Jan 27;254(3):768-72. doi: 10.1006/bbrc.1998.0131.
- Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst. 2006 Feb 15;98(4):223-5. doi: 10.1093/jnci/djj065. No abstract available.
- Karlsson JO, Brurok H, Eriksen M, Towart R, Toft KG, Moen O, Engebretsen B, Jynge P, Refsum H. Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol. 2001 Nov;42(6):540-7. doi: 10.1080/028418501127347340.
- Karlsson JO, Brurok H, Towart R, Jynge P. The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity. Cancer Res. 2006 Jan 1;66(1):598; author reply 598. doi: 10.1158/0008-5472.CAN-05-2053. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PP 01-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy
-
Hospices Civils de LyonCompletedChemotherapy Effect | G-CHOP Chemotherapy | R-CHOP ChemotherapyFrance
-
Taipei Medical UniversityCompletedChemotherapy TrainingTaiwan
-
University of RochesterTerminated
-
Universitaire Ziekenhuizen KU LeuvenFlemish League Against CancerCompletedCancer | ChemotherapyBelgium
-
McGill UniversityRossy Cancer NetworkCompleted
-
Namik Kemal UniversityCompleted
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingChemotherapy EffectFrance
-
West Cancer CenterPfizer; Emory UniversityCompletedChemotherapy EffectUnited States
-
Taipei Medical UniversityTaipei Medical University WanFang HospitalCompleted
-
Milton S. Hershey Medical CenterCompleted
Clinical Trials on Mangafodipir
-
Assistance Publique - Hôpitaux de ParisCompletedCancer | Neurotoxic DisordersFrance
-
National Institute of Neurological Disorders and...CompletedMultiple SclerosisUnited States
-
University of EdinburghUnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Ischemic CardiomyopathyUnited Kingdom
-
National Institute of Neurological Disorders and...Recruiting
-
Egetis TherapeuticsCompletedMyocardial InfarctionSweden